Skip to main content
Immunotherapy logoLink to Immunotherapy
. 2024 Oct 8;16(16-17):1079–1090. doi: 10.1080/1750743X.2024.2408048

Allogeneic CAR-T cells for cancer immunotherapy

Xinfeng Chen a,b,‡, Yaoxin Gao a,‡, Yi Zhang a,b,c,d,e,*
PMCID: PMC11492692  PMID: 39378059

ABSTRACT

Autologous chimeric antigen receptor (CAR)-modified T (CAR-T) cell therapy has displayed high efficacy in the treatment of hematological malignancies. Up to now, 11 autologous CAR-T cell products have been approved for the management of malignancies globally. However, the application of autologous CAR-T cell therapy has many individual limitations, long time-consuming, highly cost, and the risk of manufacturing failure. Indeed, some patients would not benefit from autologous CAR-T cell products because of rapid disease progression. Allogeneic CAR-T cells especially universal CAR-T (U-CAR-T) cell therapy are superior to these challenges of autologous CAR-T cells. In this review, we describe basic study and clinical trials of U-CAR-T cell therapeutic methods for malignancies. In addition, we summarize the problems encountered and potential solutions.

Keywords: : allogeneic, challenges, gene editing, malignancies, universal CAR-T cell

Plain language summary

Article highlights.

  • Autologous CAR-T cells offer promising outcomes in hematological malignancies but there are some limitations.

  • Allogeneic CAR-T cells can overcome the limitations of autologous while face obstacles in preparation.

  • Preparation of allogeneic CAR-T cells needs overcome the immune rejection in clinical application.

  • Allogeneic CAR-T cell preparation faces more challenges and it will serve as an economical cancer treatment in clinical practice.

1. Background

Chimeric antigen receptor (CAR)-T cell therapy is based on T lymphocytes engineered with CARs to recognize and promote death of target cells [1,2], regarded as a promising clinical efficacy in patients with hematological malignancies [3–6]. Food and Drug Administration (FDA) and National Medical Products Administration have approved CAR-T cell products such as axicabtagene ciloleucel, brexucabtagene autoleucel, lisocabtagene maraleucel [7–9], idecabtagene vicleucel [10–13], and ciltacabtagene autoleucel [14–16], have been approved for the treatment of refractory or relapsed (R/R) B-cell acute lymphoblastic leukemia (B-ALL), B cell non-Hodgkin's lymphoma (B-NHL), and R/R multiple myeloma [17–20] (Table 1). Although multiple CAR-T cell products have been used in clinical application, all of them are autologous CAR-T cells. Autologous CAR-T cells have several limitations in their preparation, such as a high price, time-consuming process, and the suboptimal state of T cells caused by front-line chemotherapy, which challenges the broader application of CAR-T cell therapeutic method [21–24].

Table 1.

The summary of marketed autologous CAR-T cell products.

Tradename Sponsor Target Indication Response rate Time Approved authority
Kymriah Novartis CD19 B-cell acute lymphoma leukemia;
Relapsed or refractory large B-cell lymphoma
OS: 55%, EFS: 42%, PFS: 49% 2017 FDA
Yescarta Gilead Sciences CD19 Follicular lymphoma;
Relapsed or refractory large B-cell lymphoma
ORR: 94%, CR: 79% 2017 FDA
Tecartus Gilead Sciences CD19 Mantle cell lymphoma;
B-cell acute lymphoma leukemia;
Relapsed or refractory B-cell precursor acute lymphoma leukemia.
CR: 71% 2020 FDA
Breyanzi Bristol-Myers Squibb CD19 Relapsed or refractory large B-cell lymphoma ORR:73%, CR: 53% 2021 FDA
Abecma Bristol-Myers Squibb BCMA Relapsed or refractory multiple myeloma ORR: 73% 2021 FDA
Yescarta Fosun Kite CD19 Relapsed or refractory large B-cell lymphoma   2021 NMPA
Carteyva JW Therapeutics CD19 Relapsed or refractory large B-cell lymphoma ORR: 73%, CR: 53% 2021 NMPA
Carvykti Legend Biotech Corporation BCMA Relapsed or refractory large B-cell lymphoma; Relapsed or refractory multiple myeloma PFS:77%, OS: 89% 2022 FDA
Equecabtagene Autoleucel Nanjing IASO Therapeutics BCMA Relapsed or refractory multiple myeloma ORR: 98.9%, sCR/CR: 82.4%, PFS: 85.5% 2023 NMPA
Inaticabtagene Autoleucel Injection Juventas CD19 Relapsed or refractory B-cell acute lymphoma leukemia ORR: 82.1%, CR: 66.7% 2023 NMPA
zevor-cel CARsgen Therapeutics BCMA Relapsed or refractory multiple myeloma ORR:100%, sCR:78.6, PFS: 85.7% 2024 NMPA

CR: Complete remission; EFS: Event free survival; FDA: Food and Durg Administration; NMPA: National medical products administration; ORR: Overall remission rate; OS: Overall survival; PFS: Progression free survival; sCR: Strict complete remission.

To consider the boundedness of autologous CAR-T cell products mentioned in previous studies, universal CAR-T (U-CAR-T) cells can achieve CAR-T cell therapeutic effects ranging from the “one-to-one” form to the “one-to-many” form [25]. U-CAR-T cells effectively address the limitations that hinder the dissemination of CAR-T cells, as large-scale production processes to decrease cost compared with autologous CAR-T cell (averages $373,000 to $475,000 per product) [26,27], and batch manufacturing significantly enhance the quality and accessibility of CAR-T cell products [28]. Unlike autologous CAR-T cells, T cells isolated from healthy donors are obtained to produce U-CAR-T cells using genetic engineering methods. Hence, U-CAR-T cells must overcome several obstacles to prevent severe alloimmune rejection due to MHC mismatch between the donor and recipient (Table 2). Immune rejection is one of the major obstacles to U-CAR-T cells application. For example, allogeneic CAR-T cells attack the recipient or host (graft-versus-host-disease, GvHD) and immune rejection can occur by the recipient or host (host-versus-graft reaction, HvGR), which is directly related to the safety and anti-tumor effect of U-CAR-T cells [29–32]. In this review, we provide brief insights into the preparation of U-CAR-T cells and their efficiency for tumor immunotherapy.

Table 2.

Comparison between autologous and allogeneic CAR-T cells.

Characteristic Autologous CAR-T cells Allogeneic CAR-T cells
Origin of the donor Patient Healthy donor
Preparation Complex and customized Scaled-up industrialized process
Indications Haematological malignancies; Solid tumours Haematological malignancies; Solid tumours
Persistence Longer Shorter
Cost Higher Lower
Instant provision No Yes
Treatment for T-cell malignancies Restricted Promising
Main risks CRS; CRES CRS; CRES; GvHD
Limitations Quantity and quality of T cells Lower amplification and shorter persistence

CRS: Cytokine release syndrome; CRES: CAR-T cell-associated encephalopathy syndrome; GVHD: Graft versus host disease.

2. Preparation of universal CAR-T cells

To avert GvHD and HvGR in the application of allogeneic CAR-T cells, gene- or non-gene-editing techniques have been utilized to modify healthy-donor-derived T cells (Figure 1) [33–35]. Gene-editing tools, such as zinc finger nucleases (ZFN), transcription activator-like nucleases (TALENs), CRISPR/Cas9, SLEEK and PASTE, are currently employed in the preparation of U-CAR-T cells to achieve targeted genome editing. ZFNs exist as heterodimers, with each subunit comprising a DNA-binding domain composed of three to four zinc finger proteins. Each zinc finger recognizes three bases. DNA cleavage is activated when both subunits of FokI dimerizes. However, ZFN technology suffers from a low editing efficiency, limited selectivity, and high costs owing to its time-consuming and labor-intensive target design and manufacturing processes [36,37]. TALENs, also known as heterodimers, have represented significant advancements in gene editing. Each TALEN subunit comprises an N-terminal domain and a C-terminal domain. The amino acids in the DNA recognition module have base-specific recognition capabilities that enable specific binding to the DNA sites. However, the large size of TALENs poses challenges during their assembly, cloning, and cellular delivery [38–41]. CRISPR-Cas9 is an iteration of gene-editing method. Of the existing methods, it is the most potent, cost-effective, and straightforward in terms of design and implementation. Originating from the prokaryotic innate immune system, CRISPR-Cas9 allows prokaryotes to extract and store viral DNA fragments for recognition and neutralization upon reinfection. This system consists of Cas9, crRNA, and tracrRNA. The combination of crRNA and tracrRNA forms a guide RNA, that binds to Cas9 to identify and cut target DNA sequences [42,43]. CRISPR/Cas9 has been most commonly used in recent studies because of its flexibility, maneuverability, and relative accuracy. However, off-target effects are the highest risk of the three gene-editing technologies [44–46]. SLEEK is a novel knock-in technology and achieves the highest transgene knock-in efficiency in several clinically important cell types, such as B cells, T cells and NK cells [47]. Programmable addition via site-specific targeting elements (PASTE) is a new gene editing technology based on PE gene editing technology, which can integrate large pieces of DNA into cell genome without using DNA double-strand breaks [48].

Figure 1.

Figure 1.

Generation of universal chimeric antigen receptor (CAR)-modified T (U-CAR-T) cells. CAR was transduced into T cells, and then TRAC was knocked out or downregulated to prevent graft-versus-host disease. B2M or CIITA ablation diminished immunogenicity. HLA-E/G and siglec 7 were overexpressed to inhibit the function of natural killer (NK) cells. CD52 and DCK were edited to enhance the resistance to alemtuzumab and chemotherapeutic agents, respectively. The destruction of CD7/CD5 was used to render U-CAR-T cells resilient to CD7/CD5 U-CAR-T cells. Inhibitory molecules (e.g., PD-1) were knocked out to improve the persistence of the U-CAR-T cells. Cytokines (e.g., IL-7) were overexpressed to enhance the activity of the U-CAR-T cells.

Directed CAR transgene integration has the potential to mitigate vector-mediated variegation and facilitate physiologically regulated cellular responses [49,50]. In the realm of engineering T cells with recombinant T cell receptor (TCR), orthotopically positioned TCRα and TCRβ chains facilitate TCRαβ downregulation following stimulation, resembling normal physiological T cell responses. This control is crucial to prevent activation-induced cell death or exhaustion-associated dysfunction [51]. Initially, the utilization of non-integrating adeno-associated viruses (AAVs) for delivering homology-flanked templates for CAR insertion in these models has been surpassed by advancements in non-viral engineering, which now enable CRISPR/Cas9 ribonucleoprotein (RNP)-mediated delivery of recombinant template DNA for achieving similarly precise site-specific recombination of TCRs [44,52–54]. Through the genetic manipulation of anti-CD19 CAR-T cells to eliminate the expression of their endogenous TCRs, it is feasible to achieve the intended functionality of traditional CD19-specific CAR-T cells without eliciting a response to TCR stimulation, thereby mitigating GvHD progression. As an alternative, altering the TCR β chain constant (TRBC1/2) locus can cause β chain malfunction, and in both scenarios, residual TCRαβ cells can be efficiently depleted utilizing commercially available magnetic bead techniques, yielding T-cell products with redirected specificity via CAR and significantly diminished alloreactivity [31,45,55]. In 2017, the TCR was eliminated using TALEN technology in CAR-T cells in patients with R/R B-ALL for the first clinical trial [56]. Furthermore, it has been reported that mutated forms of calcineurin subunit A (CNA) and a CD19-specific CAR into the TRAC locus to reduce GvHD of CAR-T cells showed effector function of allogeneic T cells in vitro and in vivo [57]. The inclusion of potent costimulatory domains in CAR transgenes can undermine their physiological regulation, yet animal research has demonstrated that integrating CAR genes into the TCR α constant (TRAC) locus, where they are regulated by endogenous TCR transcriptional machinery, can boost cytotoxic activity, and in precisely calibrated scenarios, may contribute to lessened exhaustion [58]. Despite CRISPR/Cas9 editing at the PD-1 locus suggesting PD-1‘s role as a haploinsufficient suppressor of T-cell lymphomagenesis in animal models, no instances of T-cell lymphoma have been documented in human trials involving PD-1 editing [59]. In the case of the TT52 CAR19 lentiviral CRISPR/Cas9 product, approximately 1% of the cells exhibited predictable translocations [55,60].

In addition to suppressing the host immune system, another strategy to boost the existence of U-CAR-T cells involves minimizing their immunogenicity. Allogeneic T cells isolated from donors are prone to rejection by the host immune system once they are recognized due to HLA mismatch [61,62]. The presence of anti-HLA antibodies can trigger the rapid clearance of mismatched donor cells, necessitating the screening and exclusion of patients who have undergone previous transplants or have received extensive blood transfusions and possess anti-HLA antibodies. Alternative banks with diverse HLA types may provide a means to circumvent specific anti-HLA antibodies directed against a particular cell batch [63]. Managing the cell-mediated responses mounted by the host's T and NK cells usually involves administering preparatory conditioning chemotherapy before cell infusion. In autologous scenarios, lymphodepletion of the host achieved via a combination of fludarabine and cyclophosphamide is considered to boost the activation and expansion of infused CAR-T cells by diminishing homeostatic competition. Hence, inhibiting HLA expression can prevent alloreactive T cells from attacking recipients [64]. Alemtuzumab, an anti-CD52 conditioning antibody, has been included in another strategy as part of serotherapy. Licensed for immunomodulation in multiple sclerosis, it is widely used in allogeneic stem cell transplantation, since CD52 is present in both T and NK cells, which suppress the immune response in recipients. By genetically disrupting both CD52 and TRAC, allogeneic T cells can evade the effects of serotherapy while the host compartment remains depleted [45]. DCK, an enzyme that metabolizes purine- and pyrimidine-based chemotherapy drugs, was knocked in order to render U-CAR-T cells resilient to purine- and pyrimidine-based chemotherapeutic agents, enabling the repetition of the lymphodepletion protocol incorporating these drugs and effectively managing host lymphocytes without compromising the survival of U-CAR-T cells. Furthermore, by suspending lymphodepletion therapy, host lymphocytes can be rejuvenated, thus mitigating the severe toxicity of U-CAR-T cells [65]. β2 microglobulin (B2M) is one of the components of MHC-I and is considered an ideal target for decreasing HvGR. Currently, TALEN and CRISPR/Cas9 are the main tools used to knock out TRAC and B2M to produce allogeneic CAR-T cells and they have shown promising responses in clinical trials. Despite the exemption of U-CAR-T cells from alloreactive T cells through B2M knockout, the absence of MHC-I on these cells triggers the activation of NK cells, making them the main perpetrators in eliminating U-CAR-T cells [66–68].

Although various strategies have been explored to mitigate or eliminate activated NK cells in recipients, suppressing all NK cells remains challenging owing to their heterogeneity. For instance, overexpression of human leukocyte antigen (HLA)-E/G and siglec7/9 in U-CAR-T cells can inhibit certain subsets of NK cells by binding to NKG2A/B receptors, but also stimulate another subset by activating NKG2C. Additional studies are therefore necessary to effectively target and inhibit activated NK cells [69,70]. CD155, an activation ligand of NK cells, was knocked out to avoid attack by host NK cells [71]. MHC-II molecules play a subordinate role in mediating the alloimmune rejection response mounted by CD4+ T cells, and their expression is controlled by regulatory factors including the ankyrin repeat-containing protein (RFXANK) and the class II MHC trans-activator (CIITA) [72,73]. Allogeneic anti-CD19 CAR-T cells, with triple-knockout of B2M, CIITA, and TRAC exhibited superior persistence to CAR-T cells with double-knockout of TRAC and B2M [64]. Nevertheless, random genome integration poses a significant risk of causing insertion mutations and disrupting the function of vital genes [42,43]. Consequently, the advancement of U-CAR-T cells hinges upon the progress made in gene-editing technology.

More than 100 preclinical and clinical trials were conducted on allogeneic CAR-T cell therapy [34]. Most trials have been aimed at hematological malignancies, with CD19 being the most commonly used target, followed by other well-established targets, including CD20, CD22, and BCMA. Additionally, new targets in development, such as CD7, CD70, and CD5, have been included in these studies. Moreover, emerging targets, such as NKG2DL, GD2, EGFRvIII, CD133, and mesothelin, show promise for the treatment of solid tumors. TALEN-engineered universal FAP-CAR-T cells facilitate the infiltration and anti-tumor activity of tumor-antigen-directed CAR-T cell immunotherapy. CRISPR-Cas9-mediated disruption of TRAC, B2M, and PD-1 augmented the efficacy of U-CAR-T cells targeted EGFRvIII in a human glioblastoma preclinical study [74,75]. Considering that some target molecules are also expressed on the surface of T cells, when targeting these molecules, the corresponding target molecules, such as CD5, CD7 and CS1, will also be knocked out in T cells to prevent U-CAR-T cells from mutually destroying each other, while preserving their effectiveness at targeting and destroying tumorigenic T cells [19,76–79]. In addition, to increase the persistence of U-CAR-T cells, immune-checkpoint-related molecules, such as PD-1, LAG3, CTLA-4 and Tim-3 [80,81], have also been knocked out. Some cytokines, such as IL-7, IL-18 and IL-12, are also overexpressed in U-CAR-T cells to enhance their function [82–85].

Moreover, CAR-T cells can be crafted using non-gene-editing methodologies, with U-CAR-T cells currently in their nascent stages of development. Celyad Oncology is at the forefront of this revolution, having unveiled CYAD-101, the world's first non-genetically edited allogeneic CAR-T cell product targeting NKG2D. This innovation involves the inhibition or elimination of TCR signaling using TCR inhibitory molecule (TIM) [86,87]. Additionally, the company has pioneered the short hairpin RNA (shRNA) platform, designed to interfere with the expression of the TCR complex CD3ζ. The data presented in trials NCT04167696 and NCT04613557 (ClinicalTrials.gov) underscore the promising applications of U-CAR-T cells. Furthermore, Legend Biotech introduced the LU-CAR platform, which disrupts the activity of endogenous TCR complexes without resorting to gene-editing techniques [88]. Additionally, Fundamenta Therapeutics has created the innovative TCR and/or HLA-I Intracellularly Sequestered CAR-T (ThisCAR-T) platform, which utilizes cutting-edge technology for retaining membrane proteins within cells [89].

Alternatively, specific subsets of T cells that exhibit exceptional potential for mitigating GvHD are promising candidates for generating U-CAR-T cells. These T cells are classified based on the structure of their TCR peptide chains, with αβ T cells containing α and β chains, and γδ T cells characterized by γ and δ chains. Although they occur at lower frequencies, γδ T cells play crucial roles in innate immune responses and anti-infection or anti-tumor reactions, independently of MHC or antigen-presenting cells (APCs) [90]. In anti-tumor immunity, γδ T cells recognize and eliminate tumor cells independently of TCRs, responding to specific tumor-associated antigens (TAAs) [91]. These properties endow T cells with inherent advantages in cellular immunotherapy for solid tumors lacking specific TAAs. Capsomidis et al. reported that GD2-CAR γδ T cells are capable of proliferating in vitro while maintaining their antigen-presenting function and GD2-targeting capability [92]. A registered phased I clinical trial (NCT04107142) is currently, utilizing allogeneic NKG2DL-targeting CAR γδ cells to target multiple solid tumors.

Double-negative T (DNT) cells are a subset of fully matured T cells that express CD3 and either αβ+ or γδ+ TCRs, but lack CD4, CD8, or CD56 [93,94]. These allogeneic DNT cells are ideal candidates for ready-to-use adoptive cellular therapy, offering scalability, donor-independent anticancer activity, cryo-preservability, HvGR resistance, and minimal off-tumor toxicity. Preclinical data suggest that anti-CD19-CAR-DNT cells have an improved safety profile and lower risk of GvHD than anti-CD19-CAR-T cells, while maintaining comparable tumor-killing abilities [95,96]. Notably, anti-CD19-CAR-DNT cells exhibited greater tumor infiltration in xenograft models, which was attributed to their CAR antigen recognition, LFA-1, and degranulation pathways [97]. This suggests their potential for the treatment of large B-cell lymphoma (LBCL), which is the most common type of lymphoma. A Phase I clinical trial has demonstrated the safety and anti-tumor potential of RJMty19, an anti-CD19 CAR-DNT cell therapy, in patients with R/R LBCL [98].

Induced pluripotent stem cells (iPSCs) have emerged as a prominent research area, exhibiting a remarkable ability to self-renew and differentiate into terminal cells, such as T and NK cells, which possess confirmed anti-tumor properties. Additionally, iPSCs offer the potential to prefabricate, inspect, and bank vast quantities of therapeutically homogeneous cells, bypassing MHC barriers [99,100]. FT819, a U-CAR-T cell product derived from iPSCs and engineered to express anti-CD19 CAR, an antibody-engaging CD16 Fc receptor, and TCR knockout, has demonstrated effective leukemia control in vitro and in mouse models, while avoiding alloreactivity [101]. As reported by Themeli et al., iPSC-derived CAR-modified T cells, which mimic the phenotype of congenital γδT cells, are capable of effectively inhibiting tumor growth in xenotransplantation models [102]. Likewise, CAR-NK cells derived from iPSCs showed remarkable tumor inhibition and prolonged survival in ovarian cancer xenograft models [103]. However, the immortality of iPSCs brings both risks and opportunities, as the tumorigenic potential of undifferentiated iPSCs remains an unresolved issue.

3. Allogeneic CAR-T cells in clinical trials

To date, all approved CAR-T cell products have been derived from autologous T cells. However, autologous CAR-T cell therapy has many limitations, such as long time-consuming preparation, high cost, and the risk of manufacturing failure. Indeed, some patients would not benefit from autologous CAR-T cell products because of rapid disease progression. An optional strategy to solve these problems is to explore allogeneic CAR-T cells originated from healthy donors (Figure 2) [104]. Based on the success of preclinical studies, a series of clinical trials have been conducted to evaluate the tolerance and efficacy of U-CAR-T cells in the treatment of malignant diseases (Table 3). It was first reported that two infants with R/R CD19+ B-ALL leukemia achieved molecular remission after received lymphodepleting chemotherapy and anti-CD52 therapy, subsequently infused with a single-dose of U-CAR-T19 cells (TALEN-mediated gene editing of the TCR α chain and CD52 gene) in 2017 [33]. These results provided a foundation for further studies of U-CAR-T cells in malignant diseases. CD52-and TCRa-edited CAR-T cells were generated using different gene-editing methods in the subsequent studies. CRISPR/Cas9-engineered U-CAR-T19 cells (negative expression of TRAC and CD52) were generated, and their anti-leukemia abilities were observed in four of six patients with B-ALL, transient grade IV neurotoxicity and skin GvHD occurred in one of these patients, respectively [55]. Fourteen (67%) of the twenty-one patients had a complete response (CR) or a CR with incomplete hematological recovery in 28 days after infusion with U-CAR-T19 cells [56]. Cytokine release syndrome (CRS), cytopenia, and low-grade GvHD were the major side effects. It is worth emphasizing that expansion of U-CAR-T cells was observed in the combined anti-CD52 antibody group.

Figure 2.

Figure 2.

Application of U-CAR-T cells. T cells were isolated from healthy donors and transduced with a virus containing CAR to generate CAR-T cells. CAR-T cells were edited with TCR or CD52 knocked out to produce U-CAR-T cells. U-CAR-T cells were expanded and purified using CD3- sorting method. U-CAR-T cells were stored in a refrigerator before administered to patients.

Table 3.

Major published trials of Allogeneic CAR-T cell therapy in hematological diseases.

Name Target Clinical trial no. Disease Pre-chemotherapy Gene edited method Cell dose Number of patients Median duration of response CR(including CRi, sCR etc.) PR SD/NR PD ORR GvHD CRS
GC027 CD7 ChiCTR1900025311 T-ALL/T-LBL Fludarabine, cyclophosphamide CRISPR/Cas9 6.2 × 106–1.5 × 107/kg 12 _ 11 1 / / / / 10
U-CAR-T19/nU-CAR-T19 CD19 NCT03229876 DLBCL/B-ALL Fludarabine, cyclophosphamide with or without etoposide and TBI CRISPR/Cas9 1–6 × 106/kg 9 _ 3 / 6   / 0 9
ALLO-715 BCMA NCT04093596 r/r MM Cyclophosphamide and ALLO-647 with or without fludarabine TALEN 40M/160M/320M/480M cells 43 8.3 months 7 / / / 24 0 24
TT52CAR19 CD19 NCT04557436 r/r B-ALL Fludarabine, cyclophosphamide and alemtuzumab CRISPR/Cas9 0.8–2.0 × 106/kg 6 _ 4 / / 2 / 2 6
UCART19 CD19 NCT02746952
NCT02808442
r/r B-ALL Fludarabine, Cyclophosphamide with or without alemtuzumab TALEN 1.1–2.3 × 106/kg
6 × 106–2.4 × 108/kg
21 4.1 months 14 / / / / 2 19
CTA101 CD19 and CD22 NCT04227015 r/r ALL Fludarabine, cyclophosphamide and alemtuzumab CRISPR/Cas9 1–3 × 106/kg 6 4.3 months (3/5, CR) 5 / 1 / 5 0 6
RD13-01 CD7 NCT04538599 T-ALL/AML/T cell lymphoma Fludarabine, cyclophosphamide and etoposide CRISPR/Cas9 1–3 × 107/kg 12 10.5 months (4/7, CR) 7 2 2 / 9 0 12
RJMty19 CD19 NCT05453669 DLBCL/HGBL Fludarabine and cyclophosphamide _ 1 × 106–2 × 107/kg 12 _ 1 3 4 4 3 0 4
ThisCART19A CD19 NCT05350787 r/r B-ALL Fludarabine, cyclophosphamide and etoposide Intracellular retention 3 × 106/kg
5 × 106/kg
8 146 days (4/7, MRD- negative) 7 / / / / / 8

AML: Acute myeloid leukemia; CR: Complete remission; CRi: Complete response with incomplete hematological recovery; CRS: Cytokine release syndrome; DLBCL: Diffuse large B-cell lymphoma; GvHD: Graft versus host disease; HGBL: High-grade B-cell lymphoma; M:106; ORR: Objective response rate; PD: Progressive disease; PR: Partial response; r/r MM: Relapsed/refractory multiple myeloma; sCR: Stringent complete remission; SD: Stable disease; T/B-ALL: T/B cell acute lymphoblastic leukemia; T-LBL: T cell lymphoblastic lymphoma.

HLA negative immune cells would be sensitively killed by NK cells. HLA-C and HLA-G are considered key molecules that mediate resistance to NK cells. Although, B2M-/TCRα- edited U-CAR-T19 cells produced equivalent anti-tumor activity compared with common CAR-T19 cells in vitro and in animal models, expansion or efficacy of B2M-/TCRα- U-CAR-T19 cells were not observed in patients with R/R B cell malignancies. HLA-A-/B- and TCRα- edited allogeneic anti-CD19 CAR-T cells prepared using the CRISPR/Cas9 method produced significant anti-leukemia activity in several patients with R/R B-ALL without GvHD or serious CRS [105]. Additionally, CRISPR/Cas9-engineerred U-CAR-T cells targeted CD19/CD22 exhibit a steerable safety profile and notable anti-leukemia activity [35].

Other U-CAR-T cell targets, such as CD7 and BCMA, have also been explored. CD7 CAR-T cell therapy has been confirmed as an effective therapeutic method for T-cell lymphoma and leukemia. Objective responses were achieved in 81.8% of the patients (9/11), and the complete response rate was 63.6% in patients with CD7+ leukemia treated with donor-derived allogeneic CD7 CAR-T cells [106]. GC027 is an “off-the-shelf” allogeneic CD7-targeted CAR-T cell product, that eliminates T-lymphoblasts in 11 of 12 patients with R/R T-cell malignancies [107]. CD52 and CD7 receptors and the b chain of the TCR were inactivated in allogeneic CD7 CAR-T cells known as BE-CAR7 cells [108]. BE-CAR7 cells showed anti-leukemia activity in several patients with relapsed leukemia and some serious adverse events including CRS, cytopenia and infections.

Several BCMA CAR-T cell products have been approved for the treatment of R/R multiple myeloma. The anti-tumor ability of allogeneic BCMA CAR-T cells has been assessed in 43 patients with R/R multiple myeloma [87]. CRS was observed in 55.8% of the treatment patients, one patient (2.3%) had grade ≥3 event, six patients (14%) had neurotoxicity with no grade ≥3 event. Twenty-four patients responded and 17 (70.8%) patients responded to high doses of CAR-T cell infusion.

In addition, off-the-shelf allogeneic CAR-T cells prepared from double-negative T-cells were conducted and evaluated in 12 patients with R/R LBCL. No serious side effects or GvHD were observed in any patients [98]. A dose-dependent anti-tumor effect was exhibited, with DL4 patients achieving an objective response (n = 3, 100%). Non-gene-edited ThisCART19A exhibited anti-leukemia activities in R/R B-ALL, with 7 of 8 patients achieving a CR without GvHD, and two patients developing a grade 3–4 of CRS [109].

In general, though allogeneic CAR-T cell therapy exhibited significant anti-tumor activity, compared with autologous CAR-T cell products, allogeneic CAR-T cells had a shorter-term persistence and durative response in vivo.

4. Conclusion

Analogous to the autologous context, allogeneic-edited cells may encounter complications and toxicities due to the antigen-binding characteristics of CARs, including on- and off-target effects. Furthermore, CRS, neurotoxicity, and GvHD may manifest days or weeks after CAR-T cell infusion. Extensive studies have mapped on- and off-target nuclease effects and reported chromosomal alterations, such as losses, gains, translocations, and other aberrations, following cell manipulation [45,110]. Moreover, in vivo CAR-T cells produced by specific mRNA and virus loaded with CAR-genes have shown efficiency for leukemia and reducing systemic toxicity in a mouse model. In vivo induced CAR-T cells can potentially overcome the abovementioned limitations of current CAR-T cell therapy [111].

In summary, although U-CAR-T cell preparation faces more challenges, it will serve as a powerful enhancer for accessible, effective, and economical cancer treatments in clinical practice.

5. Future perspective

The preparation of U-CAR-T cells using reported technologies have achieved promising results, but there are still some problems such as off-target and low amplification efficiency. In the next few years, the emergence of safer and more effective editing strategies will provide a strong help for the preparation of U-CAR-T cells. In addition, in vivo CAR-T cells will be regarded as novel “U-CAR-T cells” because in vivo CAR-T cell preparation is through system delivery carrier encoding CAR that will be directly used to transfer the patient's T cells to produce CAR-T cells in a day or two. Moreover, not only in vivo CAR-T cell can reduce the treatment cycle and cost for patients, but also circumvent graft-host reactions.

Funding Statement

This work was supported by grants from the Natural Science Foundation of China (No. 82370227, 82203548), the Key Science and Technology Program of Henan Province (No. 242102310344), the National Key R&D Program: Intergovernmental International Science and Technology Innovation Cooperation Project (No. 2022YFE0141000), and the Major Science and Technology Project of Henan Province (No. 221100310100).

Author contributions

X Chen, Y Gao, and Y Zhang designed the concept of the review article and conducted the literature search and analysis. All authors participated in the visualizing of the article, writing of the original draft, and revising and editing of the final version of the manuscript.

Financial disclosure

This work was supported by grants from the Natural Science Foundation of China (No. 82370227, 82203548), the Key Science and Technology Program of Henan Province (No. 242102310344), the National Key R&D Program: Intergovernmental International Science and Technology Innovation Cooperation Project (No. 2022YFE0141000), and the Major Science and Technology Project of Henan Province (No. 221100310100). The authors declare no potential conflicts of interest.

Competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest

  • 1.Kohl U, Arsenieva S, Holzinger A, et al. CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications. Hum Gene Ther. 2018;29:559–568. doi: 10.1089/hum.2017.254 [DOI] [PubMed] [Google Scholar]
  • 2.Reddy OL, Stroncek DF, Panch SR. Improving CAR T cell therapy by optimizing critical quality attributes. Semin Hematol. 2020;57:33–38. doi: 10.1053/j.seminhematol.2020.07.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–733. doi: 10.1056/NEJMoa1103849 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709–2720. doi: 10.1182/blood-2011-10-384388 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517. doi: 10.1056/NEJMoa1407222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a Phase I dose-escalation trial. Lancet. 2015;385:517–528. doi: 10.1016/S0140-6736(14)61403-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Bach PB, Giralt SA, Saltz LB. FDA approval of tisagenlecleucel: promise and complexities of a $475 000 cancer drug. JAMA. 2017;318:1861–1862. doi: 10.1001/jama.2017.15218 [DOI] [PubMed] [Google Scholar]
  • 8.Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–2544. doi: 10.1056/NEJMoa1707447 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–448. doi: 10.1056/NEJMoa1709866 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56. doi: 10.1056/NEJMoa1804980 [DOI] [PubMed] [Google Scholar]
  • 11.Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, Phase I–2 trial. Lancet Oncol. 2019;20:31–42. doi: 10.1016/S1470-2045(18)30864-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Bouchkouj N, Zimmerman M, Kasamon YL, et al. FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma. Oncologist. 2022;27:587–594. doi: 10.1093/oncolo/oyac054 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28:735–742. doi: 10.1038/s41591-022-01731-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;380:1726–1737. doi: 10.1056/NEJMoa1817226 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–852. doi: 10.1016/S0140-6736(20)31366-0 [DOI] [PubMed] [Google Scholar]
  • 16.Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382:1331–1342. doi: 10.1056/NEJMoa1914347 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Frey NV. Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia. Blood. 2022;140:11–15. doi: 10.1182/blood.2021014892 [DOI] [PubMed] [Google Scholar]
  • 18.Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a Phase Ib/2 open-label study. Lancet. 2021;398:314–324. doi: 10.1016/S0140-6736(21)00933-8 [DOI] [PubMed] [Google Scholar]
  • 19.Martin T, Usmani SZ, Schecter JM, et al. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2021;37:1779–1788. doi: 10.1080/03007995.2021.1953456 [DOI] [PubMed] [Google Scholar]
  • 20.Sharma P, Kanapuru B, George B, et al. FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2022;28:1759–1764. doi: 10.1158/1078-0432.CCR-21-3803 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Drent E, Themeli M, Poels R, et al. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Mol Ther. 2017;2:1946–1958. doi: 10.1016/j.ymthe.2017.04.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45–55. doi: 10.1016/j.blre.2018.11.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Siegler EL, Zhu Y, Wang P, et al. Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy. Cell Stem Cell. 2018;23:160–161. doi: 10.1016/j.stem.2018.07.007 [DOI] [PubMed] [Google Scholar]
  • 24.Lin JK, Muffly LS, Spinner MA, et al. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. J Clin Oncol. 2019;37:2105–2119. doi: 10.1200/JCO.18.02079 [DOI] [PubMed] [Google Scholar]
  • 25.Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:4129–4139. doi: 10.1182/blood-2013-08-519413 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Razan M, Aleksandr. “Off-The-Shelf” allogeneic chimeric antigen receptor T-cell therapy for B-cell malignancies: current clinical evidence and challenges. Front Oncol. 2024;14:1433432. doi: 10.3389/fonc.2024.1433432 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Depil S, Duchateau P, Grupp SA, et al. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185–199. doi: 10.1038/s41573-019-0051-2 [DOI] [PubMed] [Google Scholar]; • Of interest.
  • 28.Louie RHY, Cai C, Samir J, et al. CAR(+) and CAR(-) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies. Nat Commun. 2023;14:7767. doi: 10.1038/s41467-023-43656-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Kernan NA, Collins NH, Juliano L, et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood. 1986;68:770–773. [PubMed] [Google Scholar]; • of interest
  • 30.Alruwetei AM, Bendak K, Yadav BD, et al. Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia. Br J Cancer. 2020;123:742–751. doi: 10.1038/s41416-020-0933-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Pavlovic K, Tristan-Manzano M, Maldonado-Perez N, et al. Using Gene Editing Approaches to Fine-Tune the Immune System. Front Immunol. 2020;11:570672. doi: 10.3389/fimmu.2020.570672 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Tipanee J, Samara-Kuko E, Gevaert T, et al. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy. Mol Ther. 2022;30:3155–3175. doi: 10.1016/j.ymthe.2022.06.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(377):aam9292. doi: 10.1126/scitranslmed.aaj2013 [DOI] [PubMed] [Google Scholar]
  • 34.Morgan MA, Buning H, Sauer M, et al. Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells. Front Immunol. 2020;11:1965. doi: 10.3389/fimmu.2020.01965 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Hu Y, Zhou Y, Zhang M, et al. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2021;27:2764–2772. doi: 10.1158/1078-0432.CCR-20-3863 [DOI] [PubMed] [Google Scholar]
  • 36.Durai S, Mani M, Kandavelou K, et al. Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res. 2005;33:5978–5990. doi: 10.1093/nar/gki912 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Carroll D. Progress and prospects: zinc-finger nucleases as gene therapy agents. Gene Ther. 2008;15:1463–1468. doi: 10.1038/gt.2008.145 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Bogdanove AJ, Voytas DF. TAL effectors: customizable proteins for DNA targeting. Science. 2011;333:1843–1846. doi: 10.1126/science.1204094 [DOI] [PubMed] [Google Scholar]
  • 39.Mussolino C, Morbitzer R, Lutge F, et al. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 2011;39:9283–9293. doi: 10.1093/nar/gkr597 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Kim Y, Kweon J, Kim A, et al. A library of TAL effector nucleases spanning the human genome. Nat Biotechnol. 2013;31:251–258. doi: 10.1038/nbt.2517 [DOI] [PubMed] [Google Scholar]
  • 41.Pezzoli D, Giupponi E, Mantovani D, et al. Size matters for in vitro gene delivery: investigating the relationships among complexation protocol, transfection medium, size and sedimentation. Sci Rep. 2017;7:44134. doi: 10.1038/srep44134 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Cui Z, Liu H, Zhang H, et al. The comparison of ZFNs, TALENs, and SpCas9 by GUIDE-seq in HPV-targeted gene therapy. Mol Ther Nucleic Acids. 2021;26:1466–1478. doi: 10.1016/j.omtn.2021.08.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Gonzalez Castro N, Bjelic J, Malhotra G, et al. Comparison of the Feasibility, Efficiency, and Safety of Genome Editing Technologies. Int J Mol Sci. 2021;22(19):10355. doi: 10.3390/ijms221910355 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Torikai H, Reik A, Liu PQ, et al. A foundation for universal T-cell based immunotherapy: t cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119:5697–5705. doi: 10.1182/blood-2012-01-405365 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Poirot L, Philip B, Schiffer-Mannioui C, et al. Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies. Cancer Res. 2015;75:3853–3864. doi: 10.1158/0008-5472.CAN-14-3321 [DOI] [PubMed] [Google Scholar]
  • 46.Mollanoori H, Shahraki H, Rahmati Y, et al. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment. Hum Immunol. 2018;79:876–882. doi: 10.1016/j.humimm.2018.09.007 [DOI] [PubMed] [Google Scholar]
  • 47.Alexander GA, Samia QK, Carrie MM, et al. A highly efficient transgene knock-in technology in clinically relevant cell type. Nat Biotechnol. 2024;42:458–469. doi: 10.1038/s41587-023-01779-8 [DOI] [PubMed] [Google Scholar]; • of interest
  • 48.Matthew TNY, Eleonora II, Cian SU, et al. Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases. Nat Biotechnol. 2023;41:500–512. doi: 10.1038/s41587-022-01527-4 [DOI] [PMC free article] [PubMed] [Google Scholar]; •• of considerable interest
  • 49.Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543:113–117. doi: 10.1038/nature21405 [DOI] [PMC free article] [PubMed] [Google Scholar]; •• of considerable interest
  • 50.Schober K, Muller TR, Gokmen F, et al. Orthotopic replacement of T-cell receptor alpha- and beta-chains with preservation of near-physiological T-cell function. Nat Biomed Eng. 2019;3:974–984. doi: 10.1038/s41551-019-0409-0 [DOI] [PubMed] [Google Scholar]
  • 51.Roth TL, Puig-Saus C, Yu R, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018;559:405–409. doi: 10.1038/s41586-018-0326-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Kath J, Du W, Pruene A, et al. Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells. Mol Ther Methods Clin Dev. 2022;25:311–330. doi: 10.1016/j.omtm.2022.03.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Bunse M, Bendle GM, Linnemann C, et al. RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer. Mol Ther. 2014;22:1983–1991. doi: 10.1038/mt.2014.142 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Kamiya T, Wong D, Png YT, et al. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells. Blood Adv. 2018;2:517–528. doi: 10.1182/bloodadvances.2017012823 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Ottaviano G, Georgiadis C, Gkazi SA, et al. Phase I clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci Transl Med. 2022;14:eabq3010. doi: 10.1126/scitranslmed.abq3010 [DOI] [PubMed] [Google Scholar]
  • 56.Benjamin R, Graham C, Yallop D, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two Phase I studies. Lancet. 2020;396:1885–1894. doi: 10.1016/S0140-6736(20)32334-5 [DOI] [PMC free article] [PubMed] [Google Scholar]; •• of considerable interest
  • 57.Zhang Y, Fang H, Wang G, et al. Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells. Nat Commun. 2023;14:8491. doi: 10.1038/s41467-023-44176-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Oh SA, Senger K, Madireddi S, et al. High-efficiency nonviral CRISPR/Cas9-mediated gene editing of human T cells using plasmid donor DNA. J ExpMed. 2022;219(5):e20211530. doi: 10.1084/jem.20211530 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Wartewig T, Kurgyis Z, Keppler S, et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017;552:121–125. doi: 10.1038/nature24649 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Georgiadis C, Rasaiyaah J, Gkazi SA, et al. Base-edited CAR T cells for combinational therapy against T cell malignancies. Leukemia. 2021;35:3466–3481. doi: 10.1038/s41375-021-01282-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Hirayama AV, Gauthier J, Hay KA, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019;133:1876–1887. doi: 10.1182/blood-2018-11-887067 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Nissani A, Lev-Ari S, Meirson T, et al. Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy. J Immunother Cancer. 2021;9(5):e001743. doi: 10.1136/jitc-2020-001743 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Coles AJ, Compston A. signatories . Product licences for alemtuzumab and multiple sclerosis. Lancet. 2014;383:867–868. doi: 10.1016/S0140-6736(14)60440-2 [DOI] [PubMed] [Google Scholar]
  • 64.Kagoya Y, Guo T, Yeung B, et al. Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy. Cancer Immunol Res. 2020;8:926–936. doi: 10.1158/2326-6066.CIR-18-0508 [DOI] [PubMed] [Google Scholar]
  • 65.Valton J, Guyot V, Marechal A, et al. A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy. Mol Ther. 2015;23:1507–1518. doi: 10.1038/mt.2015.104 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Ren J, Liu X, Fang C, et al. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. Clin Cancer Res. 2017;23:2255–2266. doi: 10.1158/1078-0432.CCR-16-1300 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Ren J, Zhang X, Liu X, et al. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. 2017;8:17002–17011. doi: 10.18632/oncotarget.15218 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Tian Y, Li Y, Shao Y, et al. Gene modification strategies for next-generation CAR T cells against solid cancers. J Hematol Oncol. 2020;13:54. doi: 10.1186/s13045-020-00890-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795–799. doi: 10.1038/35869 [DOI] [PubMed] [Google Scholar]
  • 70.Meril S, Harush O, Reboh Y, et al. Targeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cells. Mol. Carcinog. 2020;59:713–723. doi: 10.1002/mc.23213 [DOI] [PubMed] [Google Scholar]
  • 71.Wang B, Iriguchi S, Waseda M, et al. Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nat Biomed Eng. 2021;5:429–440. doi: 10.1038/s41551-021-00730-z [DOI] [PubMed] [Google Scholar]
  • 72.Krawczyk M, Peyraud N, Rybtsova N, et al. Long distance control of MHC class II expression by multiple distal enhancers regulated by regulatory factor X complex and CIITA. J Immunol. 2004;173:6200–6210. doi: 10.4049/jimmunol.173.10.6200 [DOI] [PubMed] [Google Scholar]
  • 73.Watanabe N, Mamonkin M. Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There? Cancer J. 2021;27:176–181. doi: 10.1097/PPO.0000000000000511 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Choi BD, Yu XL, Castano AP, et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. Journal for Immunotherapy of Cancer. 2019;7:ARTN 304. doi: 10.1186/s40425-019-0806-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Das S, Valton J, Duchateau P, et al. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy. Frontiers in Immunology. 2023;14:ARTN 1172681. doi: 10.3389/fimmu.2023.1172681 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Cooper ML, DiPersio JF. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies. Best Pract Res Clin Haematol. 2019;32:101097. doi: 10.1016/j.beha.2019.101097 [DOI] [PubMed] [Google Scholar]
  • 77.Feldmann A, Arndt C, Koristka S, et al. Conventional CARs versus modular CARs. Cancer Immunol. Immunother. 2019;68:1713–1719. doi: 10.1007/s00262-019-02399-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Depil S, Duchateau P, Grupp SA, et al. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185–199. doi: 10.1038/s41573-019-0051-2 [DOI] [PubMed] [Google Scholar]; •• of considerable interest
  • 79.Nakazawa T, Natsume A, Nishimura F, et al. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth. Cells. 2020;9(4):998. doi: 10.3390/cells9040998 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 2018;24:563–571. doi: 10.1038/s41591-018-0010-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Rafiq S, Yeku OO, Jackson HJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847–856. doi: 10.1038/nbt.4195 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Zhang L, Kerkar SP, Yu Z, et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther. 2011;19:751–759. doi: 10.1038/mt.2010.313 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Cieri N, Camisa B, Cocchiarella F, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013;121:573–584. doi: 10.1182/blood-2012-05-431718 [DOI] [PubMed] [Google Scholar]
  • 84.Avanzi MP, Yeku O, Li X, et al. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep. 2018;23:2130–2141. doi: 10.1016/j.celrep.2018.04.051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Sukumaran S, Watanabe N, Bajgain P, et al. Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov. 2018;8:972–987. doi: 10.1158/2159-8290.CD-17-1298 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Blery M, Mrabet-Kraiem M, Morel A, et al. Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control. Open Res Eur. 2021;1:107. doi: 10.12688/openreseurope.13314.2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Mailankody S, Matous JV, Chhabra S, et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: Phase I UNIVERSAL trial interim results. Nat Med. 2023;29:422–429. doi: 10.1038/s41591-022-02182-7 [DOI] [PubMed] [Google Scholar]
  • 88.Wachsmann TLA, Meeuwsen MH, Remst DFG, et al. Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma. Blood Adv. 2023;7:6178–6183. doi: 10.1182/bloodadvances.2023010410 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Luo Y, Gao L, Liu J, et al. Donor-derived Anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a Phase I trial. EClinicalMedicine. 2024;67:102377. doi: 10.1016/j.eclinm.2023.102377 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Zhao Y, Niu C, Cui J. Correction to: Gamma-delta (gammadelta) T cells: friend or foe in cancer development? J Transl Med. 2018;16:122. doi: 10.1186/s12967-018-1491-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Di Lorenzo B, Simoes AE, Caiado F, et al. Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells. Cancer Immunol Res. 2019;7:552–558. doi: 10.1158/2326-6066.CIR-18-0647 [DOI] [PubMed] [Google Scholar]
  • 92.Capsomidis A, Benthall G, Van Acker HH, et al. Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation. Mol Ther. 2018;26:354–365. doi: 10.1016/j.ymthe.2017.12.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Zhang ZX, Yang L, Young KJ, et al. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med. 2000;6:782–789. doi: 10.1038/77513 [DOI] [PubMed] [Google Scholar]
  • 94.Lee J, Minden MD, Chen WC, et al. Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms. Clin Cancer Res. 2018;24:370–382. doi: 10.1158/1078-0432.CCR-17-2228 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Lee JB, Kang H, Fang L, et al. Developing Allogeneic Double-Negative T Cells as a Novel Off-the-Shelf Adoptive Cellular Therapy for Cancer. Clin Cancer Res. 2019;25:2241–2253. doi: 10.1158/1078-0432.CCR-18-2291 [DOI] [PubMed] [Google Scholar]
  • 96.Vasic D, Lee JB, Leung Y, et al. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities. Sci Immunol. 2022;7:eabl3642. doi: 10.1126/sciimmunol.abl3642 [DOI] [PubMed] [Google Scholar]
  • 97.Tang B, Lee JB, Cheng S, et al. Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: a first-in-human phase I study. Am J Hematol. 2022;97:E264–E267. doi: 10.1002/ajh.26564 [DOI] [PubMed] [Google Scholar]
  • 98.Xiao X, Liu H, Qiu X, et al. CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a Phase I, first-in-human study. EClinicalMedicine. 2024;70:102516. doi: 10.1016/j.eclinm.2024.102516 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Nianias A, Themeli M. Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges. Curr Hematol Malig Rep. 2019;14:261–268. doi: 10.1007/s11899-019-00528-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Sachamitr P, Hackett S, Fairchild PJ. Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy. Front Immunol. 2014;5:176. doi: 10.3389/fimmu.2014.00176 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Chang YJ, Weng CL, Sun LX, et al. Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials. Ann. Hematol. 2012;91:427–437. doi: 10.1007/s00277-011-1299-8 [DOI] [PubMed] [Google Scholar]
  • 102.Themeli M, Kloss CC, Ciriello G, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31:928–933. doi: 10.1038/nbt.2678 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Li Y, Hermanson DL, Moriarity BS, et al. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell. 2018;23:181–92 e5. doi: 10.1016/j.stem.2018.06.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Jo S, Das S, Williams A, et al. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. Nat Commun. 2022;13:3453. doi: 10.1038/s41467-022-30896-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Chen X, Tan B, Xing H, et al. Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies. Cancer Immunol Immunother. 2024;73:13. doi: 10.1007/s00262-023-03586-1 [DOI] [PMC free article] [PubMed] [Google Scholar]; •• of considerable interest
  • 106.Hu Y, Zhou Y, Zhang M, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32:995–1007. doi: 10.1038/s41422-022-00721-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Li S, Wang X, Liu L, et al. CD7 targeted “off-the-shelf” CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies. Leukemia. 2023;37:2176–2186. doi: 10.1038/s41375-023-02018-4 [DOI] [PubMed] [Google Scholar]
  • 108.Chiesa R, Georgiadis C, Syed F, et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N Engl J Med. 2023;389:899–910. doi: 10.1056/NEJMoa2300709 [DOI] [PubMed] [Google Scholar]
  • 109.Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367:6481. doi: 10.1126/science.aba7365 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Nahmad AD, Reuveni E, Goldschmidt E, et al. Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage. Nat Biotechnol. 2022;40:1807–1813. doi: 10.1038/s41587-022-01377-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Xin T, Cheng L, Zhou C, et al. In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy. Front Oncol. 2022;12:809754. doi: 10.3389/fonc.2022.809754 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Immunotherapy are provided here courtesy of Taylor & Francis

RESOURCES